APOBEC1

Across TCGA pan-cancer cohorts, APOBEC1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated APOBEC1 data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher APOBEC1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated APOBEC1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, UCEC, and LSCC are the cancer types where APOBEC1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.844	0.369	<.001	39	view →
UCEC	OS	Tertile	II,III,IV	0.499	1.000	.018	18	view →
LSCC	DFS	Median	All	0.515	0.936	.013	10	view →
HNSC	DFS	Tertile	All	0.679	0.898	.005	9	view →
CCRCC	DFS	Quartile	II,III,IV	0.904	0.536	.009	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

APOBEC1–LUAD (DFS)

Open the LUAD breakdown →